LINC 2023: Late-breaking Science Video Collection
Published: 20 June 2023
-
Views:
1028
-
Likes:
7
-
Views:
1028
-
Likes:
7
-
Up Next -
4m 51sPart 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety -
4m 48sPart 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date -
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes -
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease -
3m 49sPart 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions -
6m 6sPart 1 | Session 8 Improving Clinical Outcomes in Infrapopliteal Lesions With Cre8™ BTK -
8m 56sPart 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
About the episode
LINC 23 - In this short interview, we are joined by Dr Marianne Brodmann (Medical University of Graz, AT) to discuss the results of the ELEGANCE Registry.
Sponsored by Boston Scientific, the ELEGANCE Registry aimed to bridge the gap in knowledge by collecting real-world data from populations that have been historically underrepresented in peripheral vascular disease trials.
In this interview, Dr Brodmann focuses on the initial data obtained from the first 500 patients treated with the RANGER DCB Device. Findings suggest differences between males and females in their presentation of peripheral vascular diseases, as well as differences in risk factors for disease between ethnic groups.
Interview Questions:
- What is the unmet need you are trying to address with this registry?
- What is the patient cohort included in the ELEGANCE Registry?
- What were the key findings revealed at LINC 23?
- Were there any novel insights into any specific patient groups within this study?
- What are your take-home messages?
Recorded remotely from Graz, 2023.
Editor: Jordan Rance
Video Specialist: Dan Brent
Faculty Biographies
Marianne Brodmann
Professor, Head of the Clinical Division of Angiology
Dr Marianne Brodmann is the Head of Division of Angiology, Head of Clinical Research at Division of Angiology at the Medical University of Graz, Austria.
Dr Brodmann is a Fellow of the European Society of Cardiology, Board Member of the European Union of Medical Specialist (UEMS), past President of the ÖGA (Austrian Society of Angiology) and National Delegate of the IUA (International Union of Angiology).
Research activities include anticoagulation and thrombolysis, new endovascular technologies in the peripheral field and evaluation of the nature of restenosis. She also founded a research establishment for experimental angiology animal models at the University of Graz.
Dr Brodmann has participated in over 50 international clinical trials including Principal Investigator for the Bioflex I, Lutonix BTK and TOBA-BTK clinical trials and Steering Committee of the CVI Ingenuity trial.
Comments